Category: carcinoid and neuroendocrine tumor treatments
Carcinoid Cancer Foundation’s May 2011 Symposium Now Online
The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management: The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.
Following …
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Carcinoid Cancer Foundation Thanks Symposium Sponsors
There’s still time to register for the Carcinoid Cancer Foundation’s 14th annual symposium for patients, family, friends, and healthcare professionals, which will be held on Sunday, May 1st at Mount Sinai Medical Center in New York City. The Foundation…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
Carcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel
What are the most state-of-the-art treatments for carcinoid and NET cancer patients today? Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized…
READ MORE
Carcinoid Cancer Foundation Thanks Steve Jobs for Bringing about Greater Awareness of Neuroendocrine Cancers
Since the announcement was made earlier this month that Apple’s CEO Steve Jobs would be taking a medical leave of absence there has been significant media coverage about pancreatic neuroendocrine tumors, NET cancer, and carcinoid. Although…
READ MOREFortune Reports That Steve Jobs Sought Neuroendocrine Cancer Treatment in Switzerland
Fortune reported today, January 18, 2011, that Apple’s CEO Steve Jobs went to Basel, Switzerland in 2009 seeking treatment for neuroendocrine cancer. Read the story HERE.…
READ MORE
